Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:20 2024-04-23 am EDT 5-day change 1st Jan Change
1.425 GBX 0.00% Intraday chart for Shield Therapeutics plc -6.56% -78.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024
FTSE 100 takes hit ahead of FOMC minutes AN
Shield Therapeutics sinks as strong performance marred by data issues AN
Shield Therapeutics plc Announces Unaudited Sales Results for the Year Ended 31 December 2023 CI
Shield Therapeutics hires former Akili leader as new CFO AN
Shield Therapeutics Names New CFO MT
Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024 CI
Comptoir opens restaurant; Intercede wins contract AN
FTSE 100 Ends Higher Fueled by Energy Stocks DJ
Shield Therapeutics Chief Financial Officer Rudolf to leave AN
AIM WINNERS & LOSERS: Windward sees high contracting activity levels AN
Shield Therapeutics CFO to Step Down MT
Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023 CI
Aston Martin CEO ups stake; Alkemy's lithium deal AN
Shield Therapeutics completes USD20 million SWK financing AN
Shield Therapeutics Closes $20 Million Debt Facility with SWK Funding MT
EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy AN
Shield Therapeutics Raises $6 Million via Share Issue MT
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index DJ
Shield Therapeutics completes GBP5 million share placing AN
Shield Therapeutics raises funds for US sales push as loss narrows AN
Earnings Flash (STX.L) SHIELD THERAPEUTICS Posts H1 Revenue $4.3M MT
Earnings Flash (STX.L) SHIELD THERAPEUTICS Reports H1 Loss $-0.00 MT
Shield Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shield Therapeutics changes reporting currency to US dollars AN
Chart Shield Therapeutics plc
More charts
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0142
Average target price
-
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. STX Stock
  4. News Shield Therapeutics plc
  5. Shield Therapeutics' : New CEO Assumes Position